ANI Pharmaceuticals, Inc. (ANIP)
Automate Your Wheel Strategy on ANIP
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
Read More
ANI (ANIP) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
Published: February 27, 2026 by: Benzinga
Sentiment: Positive
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares are down early Friday following the company's strong fourth-quarter report.
Read More
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.63 per share a year ago.
Read More
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and year ended December 31, 2025.
Read More
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read More
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
Read More
ANIP Stock Rises 7% in a Week: Here's What You Should Know
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
Read More
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Positive
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary growth engine, projected to reach $540–$575 million in 2026, supported by a 90-person commercial expansion and a pivotal Phase 4 trial. ANIP's valuation is compelling at 11.2x forward P/E, a 43% sector discount, with strong liquidity ($285 million cash) and no cash burn anticipated.
Read More
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
Read More
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
Read More
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
Read More
5 Biotech Stocks to Watch for Potential Upside
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Read More
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read More
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Read More
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Read More
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
Read More
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Read More
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Read More
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Daniel Krizay - Guggenheim Securities, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Folkes …
Read More
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About ANI Pharmaceuticals, Inc. (ANIP)
- IPO Date 2000-05-05
- Website https://www.anipharmaceuticals.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Nikhil Lalwani
- Employees 897